IMBRUVICA® is indicated for the treatment of patients with Marginal Zone Lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy.

INN:

Subtype:

Marginal Zone Lymphoma (MZL)

License:

FDA

Class:

BTK inhibitor

R/R

PIhttps://www.imbruvica.com/docs/librariesprovider7/default-document-library/prescribing_information.pdf 

1. Approved Labelling

IMBRUVICA® is indicated for the treatment of patients with Marginal Zone Lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy.

2. Treatment Regimen 

The recommended dose of Imbruvica for MZL is 560mg (four 140 mg capsules) orally once daily until disease progression or unacceptable toxicity.

3. AE/Warnings

Please see section 5 of the PI.

All content on this site is intended for healthcare professionals only. If you are a patient or carer, please visit the Lymphoma Coalition.